Sunnyvale, California (ots/PRNewswire) - Premier Qatar, Latvian
Cancer Centers to Offer Patients Treatment with the CyberKnife®
System; Leading Bulgarian Hospital to Provide Treatment with the
TomoTherapy® System
Accuray Incorporated (NASDAQ: ARAY) announced today that the first
centers in Qatar, Latvia, and Bulgaria are now equipped with its
radiation therapy technology, demonstrating continued momentum in
adoption of its devices in Europe, India, the Middle East and Africa
(EIMEA). The CyberKnife® and TomoTherapy® Systems are now used in
more than 40 countries to treat patients across the full spectrum of
radiation therapy cases, from routine to complex, including brain,
breast, lung, head and neck, pancreas and prostate. With an
increasing number of centers installing the systems, more patients
will have the opportunity to benefit from the extremely precise
radiation treatments they deliver.
(Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo: http://photos.prnewswire.com/prnh/20160108/320402 )
(Photo: http://photos.prnewswire.com/prnh/20160108/320403 )
For more information on the CyberKnife and TomoTherapy Systems visit
http://www.accuray.com.
Qatar: first CyberKnife System in the Gulf Cooperation Council
The National Center for Cancer Care and Research, located in Doha, is
the first center in the region to be equipped with Accuray
technology. The installation of the CyberKnife M6(TM) Series makes it
possible for patients to receive treatment with one of the most
advanced radiation therapy systems on the market.
Latvia: first CyberKnife System in the Baltic countries
The stereotactic radiosurgery center (SRC) 'Sigulda,' located in
Sigulda, is the first center to offer CyberKnife M6 System treatments
in the Baltic region. SRC 'Sigulda' plans to use the system to treat
both oncological and non-oncological diseases.
The CyberKnife M6 Series delivers radiosurgery and stereotactic body
radiation therapy (SBRT), enabling precise, high-quality dose
distributions to be confidently administered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. Using its unique
robotic range of motion and continuous image guidance, the system
follows the target throughout the treatment process, delivering
individualized treatment with sub-millimeter precision.
Bulgaria: first TomoTherapy System in the country
The New Radiotherapy Clinic in SBALO- Specialized Hospital for Active
Treatment in Oncology, located in Sofia, will be the first hospital
in Bulgaria to offer patients treatment with the TomoTherapy® System.
SBALO selected this system because it is the only radiation system
specifically designed for image-guided intensity-modulated radiation
therapy.
Based on a CT scanner platform, the TomoTherapy® System provides
continuous delivery of radiation from 360 degrees around the patient,
or delivery from clinician-specified beam angles. These unique
features, combined with daily 3D image guidance, enable physicians to
deliver highly accurate, individualized dose distributions which
precisely conform to the shape of the patient's tumor while
minimizing dose to normal, healthy tissue, resulting in fewer side
effects for patients.
"The recent installations of Accuray technologies in Qatar, Latvia
and Bulgaria indicate clinicians believe in the long-term benefits
our devices can provide to their patients," says Lionel Hadjadjeba,
corporate senior vice president, president worldwide commercial
operations at Accuray. "We're committed to working with clinical
teams around the world to ensure that with the CyberKnife® and
TomoTherapy Systems, they can significantly and positively impact the
way cancer is managed."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation therapy
and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to market adoption of the company's products,
clinical applications, clinical results, patient outcomes and
Accuray's leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
under the heading "Risk Factors" in the company's report on Form
10-K, filed on August 28, 2015, the company's report on Form 10-Q,
filed on November 5, 2015, and the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the statements
are made and are based on information available to the company at the
time those statements are made and/or management's good faith belief
as of that time with respect to future events. The company assumes no
obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other
factors affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors should
not put undue reliance on any forward-looking statements.
ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN
